Journal Publications

NCIC CTG Publications [home]

2012

Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial (ONLINE). Ann Oncol 2012. (doi: 10.1093/annonc/mdr583)

Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial (ONLINE). The Lancet Oncology 2012.

Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in combination with HER2 and TOP2 for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res Treat 132: 225-34, 2012.

Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, Elit L, Walsh W, Sederias J, Doyle A, Eisenhauer EA, Oza AM. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 23: 238-44, 2012.

Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd FA, Tsao MS. Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer. J Thoracic Oncol 7: 316-22, 2012.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N Engl J Med 366: 399-408, 2012.

Pritchard K, Munro A, O'Malley FP, Tu D, Li X, Levine M, Shepherd L, Chia S, Bartlett J. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat 131: 541-51, 2012.

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P, for the LACE-Bio Group. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23: 86-93, 2012.

2011

Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck D-A, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC) - results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 22: 118-26, 2011.

Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS. Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803. J Clin Oncol 29: 3153-62, 2011.

Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 22: 335-40, 2011.

Booth CM, Ohorodnyk P, Zhu L, Tu D, Meyer RM. Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. Eur J Can 47: 854-63, 2011.

Bradbury P, Hilton J, Seymour L. Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clin Invest 1: 33-44, 2011.

Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-tourah AJ, Foo AH, Walsh W, Percy ivy S, Crump M, Eisenhauer EA. Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Clinical and Pharmacodynamic Phase II Multi-Center Study of the NCIC Clinical Trials Group. Leuk Lymphoma 52: 833-41, 2011.

Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 126: 453-61, 2011.

Di Leo A, Desmedt C, Bartlett JMS, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, for the HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The Lancet Oncology 12: 1134-42, 2011.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-84, 2011.

Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 22: viii49-viii51, 2011.

Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. J Clin Oncol 29: 2386-90, 2011.

Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GCE, on behalf of the Gynecologic Cancer Intergroup. Clinical Trials in Recurrent Ovarian Cancer. Int J Gynecol Cancer 21: 771-5, 2011.

Goffin J, Pond G, Tu D. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. BMC Medical Research Methodology 11: 95, 2011.

Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215-20, 2011.

Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group Study RTOG 0214. J Clin Oncol 29: 272-8, 2011.

Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for Breast-Cancer Prevention in Postmenopausal Women. N Engl J Med 364: 2381-91, 2011.

Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover (ONLINE). J Clin Oncol 2011.

Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points (ONLINE). Ann Oncol 2011.

Kouroukis CT, Fernandez LAV, Crump M, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52: 394-9, 2011.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, on behalf of Gynecologic Cancer Intergroup. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 22: 2417-23, 2011.

Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L. Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. J Thoracic Oncol 6: 1950-4, 2011.

Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DDL, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GCE, and on behalf of the Gynecologic Cancer InterGroup. Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer. Int J Gynecol Cancer 21: 763-70, 2011.

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 105: 360-5, 2011.

Li X, Chen J, Wu Y, Tu D. Constructing Nonparametric Likelihood Confidence Regions With High Order Precisions. Statistica Sinica 21: 1767-83, 2011.

Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. J Clin Oncol 29: 3605-10, 2011.

Lyerly HK, Abernethy AP, Stockler MR, Koczwara B, Aziz Z, Nair R, Seymour L. Need for Global Partnership in Cancer Care: Perceptions of Cancer Care Researchers Attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. Journal of Oncology Practice 7: 324-9, 2011.

Mackay HJ, Provencher D, Heywood M, Tu D, Eisenhauer EA, Oza AM, Meyer R. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Current Oncology 18: 84-90, 2011.

Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA. Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581. J Clin Oncol 29: 3146-52, 2011.

Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 29: 254-6, 2011.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278-85, 2011.

Pfreundschuh M, Kuhnt E, Trümper L, Õsterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, for the MabThera International Trial (MinT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology 12: 1013-22, 2011.

Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. J Clin Oncol 29: 3869-76, 2011.

Rajput AB, Hu N, Varma S, Chen C-H, Ding K, Park PC, Chapman J-AW, SenGupta SK, Madarnas Y, Elliott BE, Feilotter HE. Immunohistochemical Assessment of Expression of Centromere Protein-A (CENPA) in Human Invasive Breast Cancer. Cancers 3: 4212-27, 2011.

Razak ARA, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 104: 756-62, 2011.

Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD, for the MabThera International Trial (MinT) Group. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 22: 664-70, 2011.

Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 29: 3396-401, 2011.

Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Clin Oncol 29: 3443-9, 2011.

Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, on behalf of the participants of the 4th Ovarian Cancer Consensus Conference (OCCC). 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21: 750-5, 2011.

Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29: 279-86, 2011.

Sun X, Peng P, Tu D. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion. Contemporary Clin Trials 32: 108-13, 2011.

Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GCE, on behalf of the Gynecologic Cancer Intergroup. First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer 21: 756-62, 2011.

Tsao M-S, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson D, Rigas J, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thoracic Oncol 6: 139-47, 2011.

Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg MEL, Reed NS, Verheijen RHM, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Can 47: 57-64, 2011.

Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo (ONLINE). Eur J Can 2011. (doi:10.1016/j.ejca.2011.10.035)

Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, for the NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet 378: 2104-11, 2011.

Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, Pelletier LB, O'Brien AM, Hoskins PJ, Eisenhauer EA. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 22: 2403-10, 2011.

2010

Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, Tsao M-S, Shepherd FA, Bradbury PA. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 28: 5247-756, 2010.

Au H-J, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res 10: 119-28, 2010.

Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 28: 3472-8, 2010.

Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Vandenberg TA, Robert J, Arnold A, O'Reilly SE, Graham B, Shepherd L. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann Oncol 21: 283-90, 2010.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC Clinical Trials Group Working Group on Economic Analysis. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 102: 298-306, 2010.

Burnell M, Levine MN, Chapman J-AW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77-82, 2010.

Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao M-S, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28: 29-34, 2010.

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 4247-54, 2010.

Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 120: 427-35, 2009.

Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A Randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group study. Leukemia and Lymphoma 51: 252-60, 2010.

da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer 116: 5599-607, 2010.

de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28: 460-5, 2010.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. J Am Med Assoc 304: 1812-20, 2010.

Forster MD, Saijo N, Seymour L, Calvert H. Performing phase I clinical trials of anticancer agents: Perspectives from within the European Union and Japan. Clin Cancer Res 16: 1737-44, 2010.

Goodwin R, Ding K, Seymour L, Le Maître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group study BR24. Ann Oncol 21: 2220-6, 2010.

Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu T-E, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28: 49-55, 2010.

Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 118: 308-12, 2010.

Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 102: 1547-56, 2010.

Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28: 4674-82, 2010.

Jiang S, Tu D. Empirical likelihood confidence intervals for ratio of hazard rates under right censorship. Statistics and Its Interface 3: 455-64, 2010.

Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer 116: 362-8, 2010.

Levine MN, Chapman J-AW, O'Brien PS, Shepherd LE, Burnell MJ. Reply to C.D. Atkins "Optimal Chemotherapy for high-risk early-stage breast cancer". J Clin Oncol 28: e264, 2010.

LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 16: 1710-8, 2010.

Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, Eisenhauer EA, Oza AM. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Can 46: 1365-73, 2010.

Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 116: 163-7, 2010.

Meyer RM. Generalizing the results of cancer clinical trials (Editorial). J Clin Oncol 28: 187-9, 2010.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW, for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. J Am Med Assoc 304: 1073-81, 2010.

Miller NA, Chapman J-AW, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Lickley LA, Axelrod DE. Heterogeneity between ducts of the same nuclear grade involved by duct carcinoma in situ (DCIS) of the breast. Cancer Informatics 9: 216, 2010.

NSCLC Meta-Analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375: 1267-77, 2010.

Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions (ONLINE). J Clin Oncol 2010.

Parissenti AM, Chapman J-AW, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, Pritchard KI, Shepherd LE, Trudeau ME. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat 119: 347-56, 2010.

Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116: 3751-7, 2010.

Pujade-Lauraine E, Wagner U, Aavall-Lundquist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-9, 2010.

Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer (ONLINE). Invest New Drugs 2010.

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28: 2137-43, 2010.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz J-F, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-26, 2010

Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16: 1764-9, 2010.

Seymour L. Controversies in the design of phase II clinical trials. Clinical Advances in Hematology & Oncology 8: 95-7, 2010.

Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AMV, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 24: 237-9, 2010.

Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, Griffiths GO, Sebag-Montefiore D. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 28: 4233-9, 2010.

Tan X, Takahara G, Tu D. Optimal two-stage design for the phase II cancer clinical trials with responses and early progression as co-primary endpoints. Statistics in Biopharmaceutical Research 2: 348-54, 2010.

Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65: 353-61, 2010.

Vallance J, Lesniak SL, Belanger LJ, Courneya KS. Development and assessment of a physical activity guidebook for the Colon Health and Life-Long Exercise Change (CHALLENGE) trial (NCIC CO.21). Journal of Physical Activity and Health 7: 794-801, 2010.

van Oers MHJ, van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van't Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment relapsed/resistant follicular non-Hodgkin lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28: 2853-8, 2010.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS, EORTC-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-53, 2010.

Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA, for the NCIC Clincial Trials Group. The influence of sex on efficacy, adverse events, quality of life and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thoracic Oncol 5: 640-8, 2010.

Zhu C-Q, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao M-S. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28: 4417-24, 2010.

Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Communications in Statistics - Simulation & Computation 39: 767-76, 2010.

2009

Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-86, 2009.

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK, for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. The Lancet 374: 2055-63, 2009.

Au H-J, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 27: 1822-8, 2009.

Axelrod DE, Miller N, Chapman J-AW. Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors. Biomedical Informatics Insights 2: 11-8, 2009.

Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed SM, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, Jordan RCK, Walker M, Tu D, Parulekar W. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: A prospective randomized trial of the NCIC Clinical Trials Group (HN3). Int J Rad Oncol Biol Phys 73: 166-72, 2009.

Blake P, Swart AM, Orton J, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MKB, Amos C, Murphy C, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis (The ASTEC/EN.5 writing committee on behalf the ASTEC/EN.5 Study Group). Lancet 373: 137-46, 2009.

Booth CM, Ohorodnyk P, Eisenhauer EA. Call for clarity in the reporting of benefit associated with anticancer therapies (Correspondence). J Clin Oncol 27: e213-e214, 2009.

Booth CM, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol 27: 3938-44, 2009.

Bradbury P, Seymour L. Tumor shrinkage and objective response rates: Gold standard for oncology efficacy screening trials, or an outdated end point? The Cancer Journal 15: 354-60, 2009.

Bradbury P, Meyer R, Pater J, Tu D, Seymour L, Shepherd L, Eisenhauer E. Stopping a trial early in oncology: for patients or for industry? (letter to the editor). Ann Oncol 20: 395-6, 2009.

Chen C, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clinical Lymphoma & Myeloma 9: 74-6, 2009.

Chen E, Jones D, Gauthier I, MacLean M, Wells J, Powers J, Seymour L. Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 15: 1481-6, 2009.

Cheng M-Y, Qiu P, Tan X, Tu D. Confidence intervals for the first crossing point of two hazard functions. Lifetime Data Anal 15: 441-54, 2009.

Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N. The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psycho-Oncology 18: 554-9, 2009.

Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15: 708-13, 2009.

Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA. Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27: 404-10, 2009.

Dhani N, Tu D, Sargent J, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Cancer Res 15: 1873-82, 2009.

Douillard J-Y, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard A-S, Seymour L, LeChevalier T, Spiro S, Stephens R, Pignon JP, on behalf of the LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer. Subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thoracic Oncol 5: 220-8, 2009.

Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27: 2962-9, 2009.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: Revised RECIST guideline version 1.1. Eur J Can 45: 228-47, 2009.

Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27: 4536-41, 2009.

Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Can 45: 782-8, 2009.

Gregory J, Haesook K, Alonzo T, Gerbring R, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J. Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatric Blood & Cancer 53: 1005-10, 2009.

Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maître A, Leighl NB, Shepherd FA. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 115: 5516-25, 2009.

Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27: 2450-6, 2009.

Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: An analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 27: 4268-73, 2009.

Le Maître A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L. Anticoagulation and bleeding. A pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thoracic Oncol 4: 586-94, 2009.

Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101: 1182-92, 2009.

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Canadian Agency for Drugs and Technologies in Health 2009.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101: 644-50, 2009.

Muss HB, Berry DA, Cirrincione C, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360: 2055-65, 2009.

Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point? Eur J Can 45: 2249-52, 2009.

Pritchard KI, O'Malley F, Shepherd L, Levine MN, Tu D, Bramwell V, Andrulis I, Chia S. Response to Correspondence: "Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy" by C. Oakman, E. Moretti, C. Sotiriou, G. Viale, A. Di Leo. J Natl Cancer Inst 101: 1736-7, 2009.

Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, on behalf of the MRC CRO7/NCIC-CTG CO16 trial investigators and the NCRI colorectal cancer study group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373: 821-8, 2009.

Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872-7, 2009.

Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M, on behalf of all the trial collaborators. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373: 811-20, 2009.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-O, on behalf of the EORTC Brain Tumour and Radiation Oncology Groups and the NCIC Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-66, 2009.

Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol 27: 5109-14, 2009.

2008

Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of NCIC Clinical Trials Group trials. J Clin Oncol 26: 54-9, 2008.

Axelrod DE, Miller NA, Lickley HL, Qian J, Christens-Barry WA, Yuan Y, Fu Y, Chapman J-AW. Effect of quantitative nuclear image features on recurrence of ductal carcinoma in situ (DCIS) of the breast. Cancer Informatics 6: 99-109, 2008

Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 26: 5052-9, 2008.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-32, 2008.

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK, On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies. Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Can 44: 25-9, 2008.

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA, On behalf of the Task Force on Methodology for the Development of Innovative Cancer Therapies. Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Can 44: 19-24, 2008.

Brundage M, Bezjak A, Tu D, Palmer M, Pater J. NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting. Expert Review of Pharmacoeconomics and Outcomes Research 8: 243-53, 2008.

Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 108: 100-5, 2008

Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. J Am Med Assoc 299: 2515-23, 2008.

Chapman J-AW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100: 252-60, 2008.

Chi KN, Seymour L. Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino. Ann Oncol 19: 1813-4, 2008.

Chi KN, Ellard SL, Hotte SJ, Czaykwski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19: 746-51, 2008.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. A phase I study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833-9, 2008.

Courneya KS, Booth CM, Gill S, O'Brien P, Vardy J, Friedenreich CM, Au HJ, Brundage MD, Tu D, Dhillon H, Meyer RM. The colon health and life-long exercise change trial: a randomized trial of the NCIC Clinical Trials Group. Current Oncology 15: 262-70, 2008.

Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26: 37-43, 2008.

Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21. Contemporary Clin Trials 29: 527-36, 2008.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371: 29-40, 2008.

Eisenhauer EA, El-Maraghi RH. Predicting success in phase III studies from phase II results: A new paradigm is needed (In Reply). J Clin Oncol 26: 3654-5, 2008.

El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26: 1346-54, 2008.

Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. A clinical prognostic index for patients treated with erlotinib in National Cancer of Institute of Canada Clinical Trials Group study BR.21. J Thoracic Oncol 3: 590-8, 2008.

French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-15, 2008.

Fruh M, Rolland E, Pignon J-P, Seymour L, Ding K, Tribodet H, Winton T, LeChevalier T, Scagliotti GV, Douillard JY, Spiro S, Shepherd FA. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26: 3573-81, 2008.

Goffin JR, Tu D. Phase II stopping rules that employ response rates and early progression. J Clin Oncol 26: 3715-20, 2008.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC Trial 26981-22981/CE.3. Lancet Oncol 9: 29-38, 2008.

Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alès-Martinez JE. NCIC Clinical Trials Group MAP.3 trial: Evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7: 895-900, 2007.

Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26: 1948-55, 2008.

Hall WJ, Ding K. Sequential tests and estimates after overrunning based on p-value combination. Institute of Mathematical Statistics Collections 3: 33-45, 2008.

Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K, Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34: 442-52, 2008.

Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19: 877-82, 2008.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au H-J, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-65, 2008.

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450-6, 2008.

Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the NCIC Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 26: 265-72, 2008.

Korn EL, Liu PY, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-34, 2008.

Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen J-B, Mittmann N, Seung SJ, Crott R, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer 112: 1337-44, 2008.

Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26: 1871-8, 2008.

Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest.New Drugs 26: 249-55, 2008.

Li X, Wu Y, Tu D. A Bartlett type correction for Wald test in Cox regression model. Statistics and Probability Letters 78: 2614-22, 2008.

Liu S, Tu D. On the applications of Fisher's least significant difference (LSD) procedure in three-arm clinical trials with survival endpoints. Drug Information Journal 42: 81-91, 2008.

Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land RS, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26: 1965-71, 2008.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26: 4019-115, 2008.

Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A pooled analysis of two randomzied trials. J Clin Oncol 26: 4906-11, 2008.

Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26: 1956-64, 2008.

NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-25, 2008.

Oza AM, Eisenhauer EA, Elit L, Cutz J-C, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 26: 4319-25, 2008.

Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A, Meyer R, Saad F. Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the NCIC Clinical Trials Group. Current Oncology 15: 14-9, 2008.

Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 108: 265-9, 2008.

Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients (Correspondence). J Clin Oncol 26: 2787-8, 2008.

Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, LeChevalier T. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-9, 2008.

Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the NCIC Clinical Trials Group study BR.21. J Clin Oncol 26: 2350-7, 2008.

Zhang W, Seymour L, Chen EX. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 876: 277-82, 2008.

Zhu C-Q, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in NCIC Clinical Trials Group study BR.21. J Clin Oncol 26: 4268-75, 2008.

2007

Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: NCIC Clinical Trials Group study BR.20. J Clin Oncol 25: 4278-84, 2007.

Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110: 670-7, 2007.

Assouline S, Meyer RM, Infante-Rivard C, Connors JM, Belch A, Crump M, Kouroukis T, Eisenhauer E. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia & Lymphoma 48: 513-20, 2007.

Baetz T, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, Fisher B, Khan AZ, de Alwis DP, Weitzman A, Brail LH, Moore M. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs 25: 217-25, 2007.

Belch A, Kouroukis T, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Wright J, Eisenhauer EA. A phase II study of bortezomib in mantle cell lymphoma: the NCIC Clinical Trials Group trial IND.150. Ann Oncol 18: 116-21, 2007.

Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen (Correspondence). Cancer 109: 1927-8, 2007.

Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, Van Meerbeeck JP. Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25: 5770-6, 2007.

Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons Learned in the assessment of health-related quality of life: selected examples from the NCIC Clinical Trials Group. J Clin Oncol 25: 5078-81, 2007.

Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E. Phase II testing of sunitinib: the NCIC Clinical Trials Group IND Program Trials IND.182 - 185. Current Oncology 14: 154-61, 2007.

Chapman JW, Miller NA, Lickley HLA, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Axelrod DE. Ductal carcinoma in situ of the breast with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment. BMC Cancer 7:174, 2007. PMCID: 2001197

Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the NCIC Clinical Trials Group. J Clin Oncol 25: 1570-5, 2007.

Dudgeon DJ, Bruera E, Gagnon B, Watanabe S, Allan SJ, Warr DG, MacDonald SM, Savage C, Tu D, Pater JL. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Management 33: 365-71, 2007.

Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HCIV, Goldberg RM. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 25: 3469-74, 2007.

Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol 18: ix29-ix32, 2007.

Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D, Shepherd L. A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Ann Oncol 18: 1646-51, 2007.

Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer 55: 357-63, 2007.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: NCIC Clinical Trials Group MA.17. J Clin Oncol 25: 2006-11, 2007.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman J-AW, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP System. J Clin Oncol 25: 2127-32, 2007.

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-8, 2007.

Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA. Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the NCIC Clinical Trials Group (NCIC IND.161). Invest New Drugs 25: 471-7, 2007.

Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, Seymour L. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the NCIC Clinical Trials Group. Ann Oncol 18: 1051-5, 2007.

Macdonald DA, Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 18: 1680-4, 2007.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. J Am Med Assoc 298: 754-64, 2007.

Moore MJ, Parulekar W, Ding K. Reply to letter Erlotinib in pancreatic cancer patients: Do we need more information from the NCIC CTG trial?" by Mario Mandalà, Cecilia Moro, and Roberto Ferrettii. J Clin Oncol 25: 4320-2, 2007.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptaszynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the NCIC Clinical Trials Group. J Clin Oncol 25: 1960-6, 2007.

Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell-lung-cancer - a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 2256-61, 2007.

Osoba D, Bezjak A, Brundage M, Pater J. Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value In Health 10: S138-S145, 2007.

Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, Parmar MKB, Payne H, Savage C, Stansfeld J, Clarke NW. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/NCIC Clinical Trials Group phase III trial of adjuvant treatment after radical prostatectomy. Br J Urol International 99: 1376-9, 2007.

Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA. Adjuvant vinorelbine and cisplatin in elderly patients: NCIC Clinical Trials Group and Intergroup study JBR.10. J Clin Oncol 25: 1553-61, 2007.

Richardson H, Johnston D, Pater J, Goss P. The NCIC Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current Oncology 14: 89-95, 2007.

Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25: 313-8, 2007.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456-61, 2007.

Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd F, Reiman T. Class III ß-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 13: 994-9, 2007.

Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K, Meyer RM. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 136: 203-11, 2007.

Siu L, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E. Phase I-II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and NCIC Clinical Trials Group study. J Clin Oncol 25: 2178-83, 2007.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Rovira PS, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36, 2007.

Tai P, Chapman JW, Yu E, Jones D, Yu C, Yuen F, Lee S-J. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer 7:31, 2007. PMCID 1805760

Tsao M-S, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu C-Q, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol 25: 5240-7, 2007.

Tu D. Under-smoothed kernel confidence intervals for the hazard ratio based on censored data. Biometrical Journal 49: 474-83, 2007.

2006

Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Tsz-Tong Chan R, Fenton D, von Pawel J, Reck M, Shepherd FA. Symptom improvement in lung cancer patients treated with erolotinib: quality of life analysis of the NCIC Clinical Trials Group study BR.21. J Clin Oncol 24: 3831-7, 2006.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-14, 2006.

Chapman J-AW, Lickley HLA, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. The Breast Journal 12: 37-47, 2006.

Cheng M-Y, Hall P, Tu D. Confidence bands for hazard rates under random censorship. Biometrika 93: 357-66, 2006.

Chow E, Hoskins PJ, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: NCIC Clinical Trials Group (NCIC CTG) SC.20. Clin Oncol 18: 125-8, 2006.

Clark GM, Zborowski D, Culbertson JL, Whitehead M, Savoie M, Seymour L, Shepherd FA. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thoracic Oncol 1: 837-46, 2006.

Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small cell lung cancer in the NCIC Clinical Trials Group study BR.21. Clin Lung Cancer 7: 389-94, 2006.

Ding K, Wu Y. On the biases of change point and change magnitude estimation after CUSUM test. Journal of Statistical Planning and Inference 136: 1258-80, 2006.

Duran I, Siu LL, Oza AM, Chung T-B, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Can 42: 1875-80, 2006.

Eisenhauer EA. New targets and non-cytotoxics in ovarian cancer. Ann Oncol 17: 247-50, 2006.

Franklin J, Pluetschow A, Paus M, Specht L, Anselmo A-P, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Fermé C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 17: 1749-60, 2006.

Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) a trial of the Eastern Cooperative Oncology Group. Cancer 106: 830-8, 2006.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24: 3347-53, 2006.

Gospodarowicz MK, Meyer RM. The management of patients with limited-stage classical Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 253-8, 2006.

Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, MacLean M, Drolet DW, Rusk J, Seymour LK. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the NCIC Clinical Trials Group. Cancer Chemother Pharmacol 58: 703-10, 2006

Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintainence therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Clinical Trials Group study. Gynecol Oncol 102: 300-8, 2006.

Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99: 295-300, 2006.

Kahn HJ, Hanna WM, Chapman JW, Trudeau ME, Lickley HLA, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent AJCC breast cancer staging system. The Breast Journal 12: 294-301, 2006.

Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A NCIC Clinical Trials Group trial. Invest New Drugs 24: 435-9, 2006.

Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Matthews S, Dong R-P, Eisenhauer E. A phase II study of ZD6474 (Zactima^TM), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 24: 529-35, 2006.

Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG trial MA.19. Breast Cancer Res Treat 100: 263-71, 2006.

Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G. Phase I study of aplidine in a daily x 5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A NCIC Clinical Trials Group study: NCIC CTG IND.115.Ann Oncol 17: 1371-8, 2006.

Maroun J, Jonker D, Seymour L, Goel R, Vincent M, Kocha W, Cripps C, Fisher B, Lister D, Malpage A, Chiritescu G. A NCIC Clinical Trials Group Study - IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. Eur J Can 42: 193-9, 2006.

Mazumdar M, Tu D, Zhou XK. Some design issues of strata-matched non-randomized studies with survival outcomes. Statistics in Medicine 25: 3949-59, 2006.

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky R, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 24: 3535-41, 2006.

Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-9, 2006.

Morris DG, Bramwell VHC, Turcotte R, Figueredo AT, Blackstein ME, Verma S, Matthews S, Eisenhauer EA. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma Volume 2006 Article ID 64374: 1-7, 2006.

Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17: 1637-43, 2006.

Pater J, Parulekar W. Sentinel lymph node biopsy in early breast cancer: Has its time come?. J Natl Cancer Inst 98: 568-9, 2006.

Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24: 3629-35, 2006.

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann AH, Eisenhauer E. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-707, 2006.

Pfreundschuh MG, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P-L, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-91, 2006.

Pritchard KI, Shepherd LE, O'Malley FP, Andrulis I, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-11, 2006.

Rustin GJS, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24: 45-51, 2006.

Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, III, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Jr., Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24: 3542-7, 2006.

Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG, on behalf of the European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the NCIC Clinical Trials Group. Changing paradigms - An update on the multidisciplinary management of malignant glioma. The Oncologist 11: 180, 2006.

Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. Eur J Can 42: 1322-30, 2006.

Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Can 42: 1031-1039, 2006.

Thompson IM, Jr., Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer. A randomized clinical trial. J Am Med Assoc 296: 2329-35, 2006.

Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.

Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the NCIC Clinical Trials Group (NCIC-CTG). Ann Oncol 17: 952-6, 2006.

Tu D, Pater JL, Ingle JN, Goss PE. Randomized trial of letrozle following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer; updated findings from NCIC CTG MA.17. (NCIC CTG Response to Correspondence by Luc Vakaet) J Natl Cancer Inst 98: 1162, 2006.

van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108: 3295-301, 2006.

Whelan TJ, Goss PE, Ingle JN, Tu D, Shepherd L, Pater JL. Quality of Life in a Randomized Control Trial? Comments Concerning MA.17 (Reply letter to Editor). J Clin Oncol 24: 4038-9, 2006.

Winquist E, Knox J, Ayoub J-P, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a NCIC Clinical Trials Group investigational new drug study. Invest New Drugs 24: 159-67, 2006.

Wong RKS, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the NCIC Clinical Trials Group (SC19). J Clin Oncol 24: 3458-64, 2006.

Wong RP, Baetz T, Krahn MJ, Biagi J, Wainman N, Eisenhauer E. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 24: 347-51, 2006.

2005

Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 93: 1236-43, 2005.

Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of NCIC Clinical Trials Group and intergroup trial JBR.10 and a review of the literature. Lung Cancer 47: 385-94, 2005.

Bjarnason GA, Charpentier D, Wong R, Goel R, Douglas L, Walsh W, Matthews S, Dent S, Seymour L. Phase I study of tomudex and doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Invest New Drugs 23: 51-6, 2005.

Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, Welnicka-Jaskiewicz M, Mauriac L, Dyczka J, Cufer T, Lichinitser MR, Schornagel JH, Bonnefoi H, Shepherd L, for the EORTC Breast Cancer Group and the National Cancer Institute of Canada and Swiss Group for Clinical Cancer Research. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 6: 287-94, 2005.

Brundage M, Feldman-Stewart D, Leis A, Bezjak A, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol 23: 6949-56, 2005.

Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105: 49-53, 2005.

Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of Gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-60, 2005.

Chen EX, Batist G, Siu LL, Bangash N, MacLean M, McIntosh L, Miller WHJr, Oza AM, Lathia C, Petrenciuc O, Seymour L. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Invest New Drugs 23: 455-65, 2005.

Chen Y. Long-term quality of life assessment in post-menopausal women with primary breast cancer, 2005. Queen's University, Dept of Community Health & Epidemiology (Thesis).

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg L, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-96, 2005.

Dalal BI, Kollmannsberger,C. Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency. Br J Haematol 129: 291, 2005.

Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 23: 1859-66, 2005.

Davis A, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Hammond A, Benk V, Kandel R, Goddard K, Freeman C, Sadura A, Zee B, Day A, Tu D, Pater J. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiotherapy and Oncology 75: 48-53, 2005.

Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 16: 425-9, 2005.

Dent SF, Arnold A, Stewart DJ, Gertler S, Ayoub J, Batist G, Goss G, Neville A, Soulieres D, Jolivet J, McIntosh L, Seymour L. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Lung 183: 265-72, 2005.

Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi F, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. Chemotherapy-induced neutropenia and treatment efficay in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-77, 2005.

du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16: viii7-viii12, 2005.

Duncan G, Epstein J, Tu D, El-Sayed S, Bezjak A, Ottaway J, Pater J. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head & Neck 27: 421-8, 2005.

Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, Belanger K, Smylie M. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23(6): 569-75, 2005.

Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; NCIC Clinical Trials Group (NCIC-CTG) IND130. Invest New Drugs 23: 445-53, 2005.

Gilron I, Tu D. Response to comment by Dahl and Kehlet (Letters/Correspondence). Pain 115: 219, 2005.

Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 23: 63-71, 2005.

Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 11: 5928-34, 2005.

Goss G, Hirte H, Miller WHJr, Lorimer IAJ, Stewart D, Batist G, Parolin DAE, Hanna P, Stafford S, Friedmann J, Walsh W, Matthews S, Douglas L, Seymour LK. A phase I study of oral ZD1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the NCIC Clinical Trials Group. Invest New Drugs 23: 147-55, 2005.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97: 1262-71, 2005.

Greipp PR, San Miguel J, Durie BGM, Crowley JL, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 23: 3412-20, 2005.

Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfeller JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit form temozolomide in gliobalstoma. N Engl J Med 352: 997-1003, 2005.

Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour L. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 23: 437-43, 2005.

Karapetis C, Jonker D, O'Callaghan C. Cetuximab plus BSC versus BSC alone in the treatment of metastatic EGFR-positive colorectal cancer. Signal 6: 15-7, 2005.

Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, Eisenhauer EA. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the NCIC Clinical Trials Group. Neuro-Oncology 7: 183-8, 2005.

Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Diseases 8: 179-83, 2005.

Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, Seymour L. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 56: 154-60, 2005.

Leighl NB, Paz-Ares L, Douillard J-Y, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: NCIC Clinical Trials Group Study BR.18. J Clin Oncol 23: 2831-9, 2005.

Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of NCIC Clinical Trials Group trial MA5 Trial MA5. J Clin Oncol 23: 5166-70, 2005.

MacKenzie MJ, Hirte HW, Goss G, Maroun J, Goel R, Major PP, Miller WHJr, Panasci L, Lorimer IAJ, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (IressaTM) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23: 165-70, 2005.

Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M. Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. Clin Oncol 17: 217-8, 2005.

Meyer R, Gospodarowicz M, Connors J, Pearcey R, Bezjak A, Wells W, Burns B, Winter JN, Horning SJ, Dar R, Djurfeldt M, Ding K, Shepherd LE. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: NCIC Clinical Trials Group and Eastern Cooperative Oncology Group. J Clin Oncol 23: 4634-42, 2005

Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, for the Quality of Life Committee of the NCIC CTG. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the NCIC Clinical Trials Group. Eur J Can 41: 280-7, 2005.

Ouyang Y, Li D, Pater JL, Levine M. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer. Breast Cancer Res Treat 92: 115-23, 2005.

Parulekar WR, Day A, Ottaway J, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a NCIC Clinical Trials Group study - NCIC CTG MA.5. J Clin Oncol 23: 6002-8, 2005.

Pater JL, Goss P, Ingle J, Shelley W, Shepherd L. The ethics of early stopping rules (letter to the editor). J Clin Oncol 23: 2862-3, 2005.

Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23: 2191-2200, 2005.

Pfisterer J, Vergote I, du Bois A, Eisenhauer E, for the AGO-OVAR,NCIC CTG & EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15: 36-41, 2005.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang C-S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Sütõ T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci S, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16): 1659-72, 2005.

Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes C, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23: 4179-91, 2005.

Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U. Integration of new or experimental treatment options and new approaches to clinical trials. Ann Oncol 16: viii30-viii35, 2005.

Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J, On behalf of the Gynecological Cancer Intergroup (GCIG) Consensus Working Group. History, scope and methodology of the 3rd international consensus workshop on ovarian cancer 2004. Ann Oncol 16: viii5-viii6, 2005.

Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-32, 2005.

Singh S, Parulekar W, Murray N, Feld A, Evans WK, Tu D, Shepherd FA. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23: 850-6, 2005.

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 16: viii36-viii38, 2005.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-96, 2005

Taphoorn MJB, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer EA, Forsyth P, Bottomley A. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6: 937-44, 2005.

Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 16: viii13-viii19, 2005.

Trudeau ME, Pritchard KI, Chapman J-AW, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, Andrulis I, McCready DR, Lickley HL. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment 89, 35-45, 2005.

Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in Lung Cancer - Molecular and clinical predictors of outcome. N Engl J Med 353(2): 133-44, 2005.

Tu D, Chen J, Shi P, Wu Y. A Bartlett type correction for Rao's score test in Cox regression model. The Indian Journal of Statistics 67: 722-35, 2005.

Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the NCIC Clinical Trials Group. J Clin Oncol 23: 6881-9, 2005.

Vermorken JB, Parmar MKB, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJS, Sagae S, Verheijen RHM. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol 16: viii20-viii29, 2005.

Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M, On behalf of the GCIG representing AGO-OVAR ANZGOG EORTC-GCG GEICO GINECO GOG JGOG MRC NCIC-CTG NCI-US NSGO RTOG SGCTG. The Gynecologic Cancer Intergroup (GCIG): history and current status. Ann Oncol 16: viii39-viii42, 2005.

Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, DeAngelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16: 707-15, 2005.

Webster M, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E. Phase II trial of SarCNU in malignant glioma: Unexpected pulmonary toxicity with a novel nitrosourea. A phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs 23(6): 591-6, 2005.

Whelan T, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23: 6931-40, 2005.

Winquist E, Moore MJ, Chi K, Ernst S, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. A multinomial phase II study of Lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urologic Oncology 23: 143-9, 2005.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethume D, Ayoub J, Ding K, Seymour L, Graham B, Tsao M-S, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-97, 2005.

2004

Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Can 40: 1724-30, 2004.

Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J-A, Piccart M, Eisenhauer E. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22: 4595-603, 2004.

Byrd JC, Rai K, Peterson B, Appelbaum F, Morrison VA, Kolitz J, Shepherd L, Hines J, Schiffer C, Larson R. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2004.

Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst S, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22(3): 315-22, 2004.

Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22(12): 2461-8, 2004.

Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R. Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. A phase II study by the NCIC Clinical Trials Group (NCIC-CTG). Cancer 101: 1835-42, 2004.

Ding K, Karunamuni RJ. A linear empirical Bayes solution for the calibration problem. Journal of Statistical Planning and Inference 119: 421-47, 2004.

Douillard J-Y, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Van Vreckem A, Seymour L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46: 361-8, 2004.

Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a NCIC Clinical Trials Group trial, IND 131. Ann Oncol 15(7): 1115-22, 2004.

Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, Eisenhauer E. Phase I study of OSI-211 given as an intravenous infusion days 1, 2 and 3 every three weeks in patients with solid cancers. Invest New Drugs 22: 263-75, 2004.

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol 22(10): 1797-806, 2004.

Goffin JR, Savage C, Tu D, Shepherd L, Whelan TJ, Olivotto IA. The difference between study recommendations, stated policy, and actual practice in a clinical trial. Ann Oncol 15: 1267-73, 2004.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. Obstetrical & Gynecological Survey 59: 201-3, 2004.

Goss PE, Ingle JN, Pater JL. Letrozole in breast cancer (author's reply to letter to the editor). N Engl J Med 350: 728-9, 2004.

Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Malliard JA, Bushey TIL, Nair S, Christensen B. An eicosapentainoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and NCIC Clinical Trials Group collaborative effort. J Clin Oncol 22(12): 2469-76, 2004.

Le LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, Eisenhauer EA, Moore MJ. Phase I and pharmacokinetic study of fostriecin given as an intervenous bolus daily for five consecutive days. Invest New Drugs 22(2): 159-67, 2004.

Ma BBY, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14: 650-8, 2004.

MacKenzie MJ, Hirte HW, Siu LL, Gelmon K, Ptaszynski M, Fisher B, Eisenhauer E. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 15(4): 665-70, 2004.

Martenson JA, Jr., Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR, Jr., Fisher B, Benson AB, III, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: Results of intergroup protocol 0130. J Clin Oncol 22: 3277-83, 2004.

Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumour studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96(13): 990-7, 2004.

Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K. Phase III study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy] Ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: NCIC Clinical Trials Group Study MA.19. J Clin Oncol 22(2): 269-76, 2004.

Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) (Correspondence). J Natl Cancer Inst 96(6): 487-8, 2004.

Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ, Shustik C, Sadura A, Shepherd L, Ding K, Meyer RM, Belch AR. Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10: 8170-6, 2004.

2003

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927-34, 2003.

Bacon M, James K, Zee B. A comparison of the incidence, duration and degree of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer 13: 428-34, 2003.

Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the NCIC Clinical Trials Group. Ann Oncol 14(12): 1762-7, 2003.

Belanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Soulieres D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs 21(4):473-80, 2003.

Biagi J, Eisenhauer E. Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 13(suppl 2): 231-40, 2003.

Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval D, Drijkoningen D, Larsimont D, Piccart M. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14(3): 406-13, 2003.

Brundage M, Leis A, Bezjak A, Feldman-Stewart D, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Cancer patients' preferences for communicating clinical trial quality of life information: a qualitative study. Quality of Life Research 12: 395-404, 2003.

Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the NCIC Clinical Trials Group. J Clin Oncol 21(16): 3066-71, 2003.

Daneshmand M, Parolin DAE, Hirte HW, Major P, Goss G, Stewart D, Batist G, Miller WHJr, Matthews S, Seymour L, Lorimer IAJ. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 9: 2457-64, 2003.

Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 21: 85-97, 2003.

Ding K. A lower confidence bound for the change point after a sequential CUSUM test. Journal of Statistical Planning and Inference 115: 311-26, 2003.

Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors J, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21(4): 607-14, 2003.

Eckhardt G, Eisenhauer E, Parulekar WR, Pazdur R, Hirschfeld S. Developmental theraputics: Successes and failures of clinical trial designs of targeted compounds. ASCO Educational Book 209-19, 2003.

Eisenhauer E. Front-Line chemotherapy for ovarian cancer: which regimen and which route? ASCO Educational Book 376-84, 2003.

Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335-42, 2003.

Evans WK, Coyle D, Gafni A, Walker H and the National Cancer Institute of Canada Clinical Trials Group Working Group on Economic Analysis. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the NCIC Clinical Trials Group's Working Group on Economic Analysis. Chronic Dis Can 24(4), 102-107, 2003.

Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a NCIC Clinical Trials Group trial, IND 129. Ann Oncol 14: 543-8, 2003.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793-1802, 2003.

Gridelli C, Gallo C, Shepherd F.A., Illiano A, Piantedosi F, Robbiati S, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello G, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN investigators and the NCIC Clinical Trials Group. J Clin Oncol 21(16): 3025-34, 2003.

Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM. Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(9): 1740-1745, 2003.

Kristensen GB, Vergote I, Stuart G, del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/ carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(suppl 2): 172-7, 2003.

Moore M, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the NCIC Clinical Trials Group. J Clin Oncol 21(17): 3296-302, 2003.

Olivotto I, Chua B, Elliott EA, Parda DS, Pierce LJ, Shepherd L, Vallow LA, White JR, Whelan T. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer: the MA20 trial. Clin Breast Cancer 4(5): 361-3, 2003.

Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund JT, Eisenhauer E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer. An NCIC clinical trials group study (NCIC IND.116). Gynecol.Oncol 89(1): 129-133, 2003.

Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer - another step forward. J Natl Cancer Inst 95(24): 1811-2, 2003.

Pater JL, Pritchard KI. Optimal chemotherapy for women with breast cancer: the plot thickens. J Clin Oncol 21(6): 963-4, 2003.

Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13(Suppl 2): 144-8, 2003.

Pritchard K, Levine M, Tu D. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: Will it play in Peoria? Part II. J Clin Oncol 21(3): 399-400, 2003.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-57, 2003.

Rothenberg M, Liu PY, Braly PS, Wilczynski S, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21(7): 1313-9, 2003.

Seymour L. Epidermal growth factor receptor inhibitors: An update on their development as cancer therapeutics. Current Opinion in Investigational Drugs 4(6): 658-66, 2003.

Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7): 397-406, 2003.

Stadler W, Lerner SP. Perioperative chemotherapy in locally advanced bladder cancer (Commentary). Lancet 361: 1922-3, 2003.

Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 14: 766-74, 2003.

Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol 21: 843-50, 2003.

Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21(8): 1524-9, 2003.

Tsao MN, Sultanem K, Chiu D, Copps F, Dixon P, Easton D, Haddad P, Hayter C, Hoegler D, Wong R. Supportive care management of brain metastases: What is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada workshop on symptom control in radiation oncology. Clin Oncol 15: 429-34, 2003.

Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-39, 2003.

Wright JR, McKenzie M, DeAngelis C, Foroudi F, Paul N, Rajaraman M, Wong F, Wong R, Wong KSR. Radiation induced mucositis: co-ordinating a research agenda. Clin Oncol 15(8): 473-7, 2003.

Wu J, Bezjak A, Chow E, Cross P, Genest P, Grant N, Kirkbride P, Roy I, Whelan T, Fitzgibbon E, Wong R. A consensus development approach to define national research priorities in bone metastases: proceedings from NCIC CTG workshop. Clin Oncol 15(8): 496-499. 2003.

Yee K, Pater J, Pho L, Zee B, Siu L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 21(8): 1618-23, 2003.

2002

Belanger K, Moore M, Baker SD, Dionne J, MacLean M, Jolivet J, Siu L, Soulieres D, Wainman N, Seymour L. Phase I and pharmacokinetic study of a novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 20(10): 2567-74, 2002.

Bezjak A, Dixon P, Brundage M, Tu D, Palmer M, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater J. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Rad Oncol Biol Phys 54(3): 719-28, 2002.

Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, MacIntosh LW, Geary RS, Eisenhauer EA. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group Study Clin Cancer Res 8: 2188-92, 2002.

Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a NCIC Clinical Trials Group study. Leukemia & Lymphoma 43(8): 1595-1601, 2002.

Davis A, O'Sullivan B, Bell R, Turcotte R, Catton C, Wunder J, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel R, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 20(22): 4472-7, 2002.

El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, MacKenzie R, Read N, Berthelet E, Lau H, Epstein J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu D, Pater J. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20(19): 3956-63, 2002.

Freidlin B, Dancey J, Korn E, Zee B, Eisenhauer E. Multinomial phase II trial designs. J Clin Oncol 20(2): 599, 2002.

Fung KFM, Eisenhauer E, Elit L, Hirte H, Rosen B. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - a systemic review of the evidence from randomized trials. European J Gyne Oncol 23(2): 2002.

Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art. Ann Oncol 13: 1699-716, 2002.

O'Sullivan B, Davis A, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B. Pre-operative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomised trial. Lancet 359(9325): 2235-41, 2002.

Parulekar W, Eisenhauer E. Novel endpoints and design of early clinical trials. Ann Oncol 13 (Suppl. 4): 139-43, 2002.

Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20(4): 966-72, 2002.

Quirt I, Bodurtha A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Steward W, Eisenhauer E. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the NCIC Clinical Trials Group. Invest New Drugs 20: 431-7, 2002.

Roche K, Paul N, Smuck B, Whitehead M, Zee B, Pater J, Hiatt M, Walker H. Factors affecting workload of cancer clinical trials: results of a multicenter study of the NCIC Clinical Trials Group. J Clin Oncol 20(2): 545-56, 2002. (Abstract)

Seymour L. New targets and new therapeutics. Oncologica Clinica 7: 717-8, 2002.

Seymour L. Non-small cell cancer: Current approaches and future treatment. Oncologica Clinica 7: 718-9, 2002.

Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Current Pharmaceutical Design 8(25): 2279-84, 2002.

Seymour L. Gefitinib: A Viewpoint (Guest Commentary). Drugs 62: 2249, 2002.

Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B. Prospective, randomized, double-blind, placebo controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the NCIC Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20(22): 4434-9, 2002.

Stadler W, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology 7: 153-7, 2002.

Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk M, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the NCIC Clinical Trials Group. Classic Papers & Current Comments 7(1): 53-62, 2002.

Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8: 2530-5, 2002.

Tozer RG, Burdette-Radoux S, Belanger K, Davis ML, Lohmann RC, Rusthoven JR, Wainman N, Zee B, Seymour L. A randomized phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma. Invest New Drugs 20: 407-12, 2002.

Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, Lebwohl D, Fisher B, Seymour L. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 84(2): 327-31, 2002.

Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer. J Am Med Assoc 287(3): 321-8, 2002.

Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Research 62: 3005-8, 2002.

2001

Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early-progression. J Clin Oncol 19(3): 785-91, 2001.

Duivenvoorden WCM, Hirte HW, Singh G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int J Cancer 91(6): 857-62, 2001.

Eisenhauer E. From the molecule to the clinic -- inhibiting HER2 to treat breast cancer. N Engl J Med 344(11): 841-2, 2001.

Eisenhauer E, Dancey J. Impact of new non-cytotoxics in the treatment of ovarian cancer. Int J Gynecol Cancer 11(Suppl.1): 68-72, 2001.

Gortzak E, Azzarelli A, Buesa J, Bramwell VHC, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, the EORTC Soft Tissue Bone Sarcoma Group and the NCIC Clinical Trials Group/Canadian Sarcoma Group. A randomised phase II study on neo-adjuvant chemotherapy for 'high risk' adult soft-tissue sarcoma. Eur J Can 37(9): 1096-103, 2001.

Kiebert G, Wait S, Bernhard J, Bezjak A, Cella D, Day R, Houghton J, Moinpour C, Scott C, Stephens R. Practice and policy of measuring quality of life and health economics in cancer clinical trials: A survey among co-operative trial groups. Quality of Life Research 9: 1073-80, 2001.

Knowling M, Browman G, Siu L, Khoo K, Cooke A, Tannock I, Klaassen D, Cripps C, Goss G, Matthews S, Clarke R, Seymour L. A NCIC Clinical Trials Group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. Ann Oncol 12: 919-22, 2001.

Levine M, Bramwell V, Pritchard K, Norris B, Shepherd L, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CKO, Tu D. Randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer. Classic Papers & Current Comments 5: 694-702, 2001.

Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the NCIC Clinical Trials Group and the Southwest Oncology Group. Classic Papers & Current Comments 6(1): 169-77, 2001.

Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113: 1020-34, 2001.

Pater J, Browman G, Brouwers M, Nefsky M, Evans W, Cowan D. Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol 19(14): 3392-6, 2001.

Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PLD, Bramwell VHC, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer:  a report of the National Cancer Institute of Canada Clinical Trials Group. Classic Papers & Current Comments 5(4): 658-68, 2001.

Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group trial 9416 (intergroup trial 0160). J Thoracic Cardiovascular Surg 121(3): 472-83, 2001.

Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller D, Shepherd L, Seitz J, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-7, 2001.

Seymour L. Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents. Current Drug Targets 2: 117-33, 2001.

Seymour L, Eisenhauer E. A review of dose limiting events in phase I trials: Antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 47(1): 2-10, 2001.

Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E. Phase II study of Pemetrexed Disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. A study of the NCIC Clinical Trials Group. Cancer 92(3): 595-600, 2001.

Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordinal categorical clinical endpoints. Journal of Statistical Research 35(1): 65-77, 2001.

Tu D. Rao's score tests in survival analysis: examples and Bartlett type adjustments. Communications in Statistics-Theory & Methods 30: 1521-32, 2001.

Vermorken J. Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer 11(Suppl. 1): 73-6, 2001.

Vermorken J, Eisenhauer E. Current developments in the treatment of cervical cancer. CME J Gynecol Oncol Chapter 18 Part 2: 52-60, 2001.

2000

Bramwell V, Andrulis I, Bell R, Eisenhauer E, Fornasier V, Kandel R, O'Sullivan B, Temple W, Turcotte R, Wunder J. Canadian Sarcoma Group Workshop. Sarcomas: molecular markers to therapeutics, 26-27 February 2000, Toronto, Canada. Sarcoma 4: 67-73, 2000.

Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 11(1): 65-8, 2000.

Eisenhauer E, Vermorken J. Principles and process of cancer drug development. CME J Gynecol Oncol Chapter 18 Part 1: 344-50, 2000.

Eisenhauer E. Phase I and II evaluation of novel anticancer agents:  are response and toxicity the right endpoints? Onkolgie 23(suppl 3): 2-6, 2000.

Eisenhauer E. New cytotoxics and non-cytotoxics in epithelial ovarian cancer. Int J Gynecol Cancer 10 (Suppl 1): 38-43, 2000.

Eisenhauer E, O'Dwyer P, Christian M, Humphrey J. Phase I clinical trial design in cancer drug development. J Clin Oncol 18(3): 684-92, 2000.

Evans W, Dahrouge S, Stapleton J, Quinn C, Pollock D, Waterfield B, Lister D, Hansel F, Smith A. An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer 28: 85-95, 2000.

Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett WEN, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever M. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96(9): 2981-6, 2000.

Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18(12): 2395-405, 2000.

Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumours. J Clin Oncol 18(24): 4098-108, 2000.

Gertler SZ, Macdonald D, Goodyear M, Forsyth P, Stewart D, Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L. NCIC CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11(3): 315-8, 2000.

Hirte H, Goel R, Major P, Seymour L, Huan S, Stewart D, Yau J, Arnold A, Holohan S, Waterfield B, Bates S, Bennett K, Walsh W, Elias I. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 11(12): 1579-84, 2000.

Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Instutute of Canada Clinical Trials Group study. J Clin Oncol 18(24): 4038-44, 2000.

Johnston JB, Eisenhauer E, Wainman N, Corbett WEN, Zaentz D, Daeninck PJ. Long-term outcome following treatment of hairy-cell leukemia with pentostatin (Nipent): a NCIC Clinical Trials Group study. Semin Oncol 27(2)(Suppl 5): 32-6, 2000.

Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE, Dar AR. Dexamethasone for the prophylaxis of radiation-induced emesis - a NCIC Clinical Trials Group phase III study. J Clin Oncol 18(9): 1960-6, 2000.

Miller WH, Reyno L, Batist G, Loewen G, Cato J, Jaunakais D, Parker BA, Truglia J, Beare S, Matthews S, Dancey J, Eisenhauer E. A phase I study of 9-cis-retinoic acid and interferon alpha in patients with renal cell carcinoma:  an NCIC Clinical Trials Group study. Ann Oncol 11: 1387-9, 2000.

Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: a NCIC Clinical Trials Group study MA8. J Clin Oncol 18: 2385-94, 2000.

Osoba D. Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer 8: 84-8, 2000.

Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J-A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9): 699-708, 2000.

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343(24): 1750-7, 2000.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95(1): 90-5, 2000.

Therasse P, Arbuck SG, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-16, 2000.

Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190: 150-6, 2000.

Tu D, Shalay K, Pater J. Adjustment of treatment effect for covariates in clinical trials: statistical and regulatory issues. Drug Information Journal 34(2): 511-23, 2000.

Vergote I, Rustin G, Eisenhauer E, Kristensen G, Pujade-Lauraine E, Parmar M, Friedlander M, Jakobsen A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92(18): 1534-5, 2000.

Vincent M, Bramwell V, Moran L. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Current Oncology 7(3): 149-61, 2000.

1999

Armand J-P, Seymour L, Evans TRJ. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. Eur J Can 35(Suppl 1): 14-8, 1999.

Berek J, Bertelsen K, du Bois A, Brady F, Carmichael J, Eisenhauer E, Gore M, Grenman S, Hamilton T, Hansen SW, Harper P, Horvath G, Kaye S, Lück H-J, Lund B, McGuire WP, Neijt J, Ozols R, Parmar M, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin G, Sessa C, Thigpen T, Trope C, Tuxen M, Vergote I, Vermorken J, Willemse PHB. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10: 87-92, 1999.

Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Research 59(3): 684-8, 1999.

Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, Iglesias J, Fisher B, Eisenhauer EA. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 10: 1175-9, 1999.

Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a NCIC Clinical Trials Group study. Leukemia 13: 343-7, 1999.

Eisenhauer E, Gore M, Neijt J. Ovarian Cancer:  Should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10(Suppl 1): 9-15, 1999.

Erlichman C, Marsoni S, Seitz J, Skillings J, Shepherd L, Zee B, Milan C, Bedenne L, Giovanni M, LeTruet Y, Torri V, Tardio B, Zaniboni A, Pancera G, Martignoni G, O'Connell M, Kahn M, Francini G. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. By the International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17(5): 1356-63, 1999.

Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. A randomized study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17: 3038-47, 1999.

Gelmon K, Eisenhauer E, Harris A, Ratain M, Workman M. Anticancer agents targeting signaling molecules and cancer cell environment:  challenges for drug development? J Natl Cancer Inst 91(15): 1281-7, 1999.

Hoskins PJ, Eisenhauer EA, van Glabbeke M, Vermorken JB, Tu D, James K. Predicting outcome after initial relapse of epithelial ovarian cancer: can we identify patients who will not benefit from further therapy? CME J Gynecol Oncol Chapter 13 Part 1: 64-8, 1999.

Hospers GAP, Eisenhauer E, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 80(5/6): 629-38, 1999.

International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354: 533-40, 1999.

James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors:  unidimensional versus bidimensional measurement. J Natl Cancer Inst 91(6): 523-8, 1999.

Kaye S, Eisenhauer E, Hamilton T. New non-cytotoxic approaches to ovarian cancer. Ann Oncol 10(Suppl 1): 65-8, 1999.

Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of N,N-diethyl-2[4-(phenylmethyl)phenoxy]ethanamine HCI (DPPE) and doxorubicin chemotherapy in metastatic breast cancer. A NCIC Clinical Trials Group  study. J Clin Oncol 17(11): 3431-7, 1999.

Kirkbride P, Gelmon K, Eisenhauer E. Paclitaxel (Taxol) and concurrent radiotherapy in locally advanced non-small cell lung cancer - the Canadian experience. Semin Radiat Oncol 9 (2 Suppl 1): 102-7, 1999.

MacNeil M, Eisenhauer E. High dose chemotherapy: Is it standard management for any common solid tumor? Ann Oncol 10: 1145-61, 1999.

Michael M, Babic B, Khokha R, Tsao MS, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17(6): 1802-8, 1999.

Moore M, Winquist E, Murray N, Tannock I, Huan S, Bennett K, Walsh W, Seymour L. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer. A phase II trial of the NCIC Clinical Trials Group. J Clin Oncol 17(9): 2876-81, 1999.

Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the NCIC Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17(8): 2300-8, 1999.

Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores; lessons from adults. Int J Cancer 83(suppl): 132-7, 1999.

Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.

Piccart M, Stuart G, Cassidy J, Bertelsen K, Parmar M, Eisenhauer E, Kaye S, Trope C, Swenerton K, Harper P, Vermorken J. Intergroup collaboration in ovarian cancer: a giant step forward. Ann Oncol 10(Suppl 1): 83-6, 1999.

Quon H, Shepherd F, Payne D, Coy P, Murray N, Feld R, Pater J, Sadura A, Zee B. The influence of age on the delivery, tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Rad Oncol Biol Phys 43(1): 39-45, 1999.

Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multi-targeted antifolate LY231514 as a first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17: 1194-9, 1999.

Seymour L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 25(5): 301-12, 1999.

Seymour L, Bramwell V, Moran L. Use of dexrazoxane in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prevention & Control 392: 145-9, 1999.

Zee B, Melnychuck D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J Biopharmaceutical Statistics 9(2): 351-63, 1999.

1998

Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 78(11): 1479-87, 1998.

Bramwell V, Blackstein M, Belanger K, Verma S, Beare S, Eisenhauer E. A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 2: 29-33, 1998.

Crump M, Gluck S, Pritchard K, Shepherd L, Pater J. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America (letter to the editor). J Clin Oncol 16(2): 800-1, 1998.

Eisenhauer E. Cytoprotection. European Society for Medical Oncology Educational Book, 109-113, 1998.

Eisenhauer E. Phase I and II trials of novel anticancer agents: endpoints, efficacy and existentialism. The Michael Clavel Lecture. Ann Oncol 9(10): 1047-52, 1998.

Eisenhauer E, Vermorken J. The Taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55(1): 5-30, 1998.

Eisenhauer EA, Ten Bokkel-Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Classic Papers & Current Comments 3: 171-84, 1998.

Hoskins P, Tu D, James K, Pater J, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol Oncol 70: 224-30, 1998.

Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a NCIC Clinical Trials Group Study. J Clin Oncol 16(6): 2233-7, 1998.

Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16(3): 1174-8, 1998.

Levine M, Pritchard K, Bramwell V, Shepherd L. Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer (in reply letter to the editor). J Clin Oncol 16(12): 3917, 1998.

Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16(8): 2651-8, 1998.

Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci A, Cassileth P, Crowther D, Diehl V, Fisher R, Hoppe R, Jacobs P, Pater J, Pavlovsky S, Thompson E, Wiernik P. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16(3): 818-29, 1998.

Maroun JA, Stewart D, Verma S, Eisenhauer E. Phase I clinical study of didemnin B A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 16: 51-6, 1998.

Meta Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer; effect of administration schedule and prognostic factors. J Clin Oncol 16(11): 3537-41, 1998.

Meta Analysis Group in Cancer. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1): 301-8, 1998.

O'Connell M, Laurie J, Kahn M, Fitzgibbons R, Erlichman C, Shepherd L, Moertel CG, Kocha W, Pazdur R, Wieand H, Rubin J, Vukov A, Donohue JH, Krook J, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. Highlights of clinical gastrointestinal cancer research. Classic Papers & Current Comments 1998.

O'Connell MJ, Laurie J, Kahn M, Fitzgibbons R, Erlichman C, Shepherd L, Moertel CG, Kocha W, Pazdur R, Wieand H, Rubin J, Vukov A, Donohue JH, Krook J, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1): 295-300, 1998.

Osoba D, Zee B. Completion rates in health-related quality-of-life assessment:  approach of the NCIC Clinical Trials Group. Statistics in Medicine 17: 603-12, 1998.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1): 139-44, 1998.

Pater J, Osoba D, Zee B, Lofters W, Gore M, Dempsey E, Palmer M, Chin C. Effects of altering the time of administration and the timeframe of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Quality of Life Research 7(3): 273-8, 1998.

Shepherd FA, Eisenhauer E. Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. Semin Oncol 25(1 Suppl 2): 2-7, 1998.

Shepherd FA, Johnston M, Payne D, Burkes R, Deslauriers J, Cormier Y, Diaz de Bedoya L, Ottaway J, James K, Zee B. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small cell lung cancer:a NCIC Clinical Trials Group study. Br J Cancer 78(5): 683-5, 1998.

Shustik C. Interferon in the treatment of multiple myeloma. Cancer Control 5(3): 226-34, 1998.

Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ. Phase I and pharmacological study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16: 1122-30, 1998.

Tu D. On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints. J Biopharmaceutical Statistics 8(2): 263-82, 1998.

Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Can 34(12): 1871-5, 1998.

Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 16(8): 2834-9, 1998.

Zee B. Growth curve model analysis for quality of life data. Statistics in Medicine 17: 757-66, 1998.

1997

Bacon M. The evolving role of nurses in clinical trials. Can Onc Nursing J 7(2): 79-80, 1997.

Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 1638-45, 1997.

Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W, Pritchard KI. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44: 201-10, 1997.

Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater J. Quality of life scores:  an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Quality of Life Research 6(2): 151-8, 1997.

Einhorn LH. (Guest Editor). Highlights of lung cancer research. Classic Papers & Current Comments 2(1): 21-30, 1997.

Eisenhauer E, Vermorken J. New cytotoxic drugs. South Am J of Cancer 1: 17-32, 1997.

Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-8, 1997.

Goss P, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, James K, Paul K, Rodgers A, Pritchard K. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol 41(1): 53-60, 1997.

Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H. A phase I/II study of paclitaxel (Taxol) and concurrent radiotherapy in advanced non small cell lung cancer. Int J Rad Oncol Biol Phys 39(5): 1107-11, 1997.

Lofters W, Pater J, Zee B, Dempsey E, Walde D, Moquin J, Wilson K, Hoskins P, Guevin R, Verma S, Navari R, Krook J, Hainsworth J, Palmer M, Chin C. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8): 2966-73, 1997.

Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Supportive Care in Cancer 5: 307-13, 1997.

Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15(1): 116-23, 1997.

Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.

Pater JL, Zee B, Palmer M, Johnston D, Osoba D. Fatigue in patients with cancer: results with NCIC Clinical Trials Group Studies employing the EORTC QLQ-C30. Supportive Care in Cancer 5: 410-3, 1997.

Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin J-P, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. The role of 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8: 181-5, 1997.

Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PLD, Bramwell VHC, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 2302-11, 1997.

Sawka CA, Pritchard KI, Shelley W, DeBoer G, Paterson AHG, Meakin JW, Sutherland DJA. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women:  A report of the NCIC Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 44(3): 211-5, 1997.

Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell V, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, van Glabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma:  a study of the European Osteosarcoma Intergroup. Lancet 350(9082): 911-7, 1997.

Tallman M, Andersen J, Schiffer C, Appelbaum F, Feusner J, Ogden A, Shepherd L, Willman C, Bloomfield C, Rowe J, Wiernik P. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-8, 1997.

Tepper JE, O'Connell MJ, Petroni G, Hollis D, Cooke E, Benson AB, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer:  initial results of Intergroup 0114. J Clin Oncol 15(5): 2030-9, 1997.

Tsao MS, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3(10): 1807-14, 1997.

Tu D. A comparative study of some statistical procedures in establishing therapeutic equivalence of nonsystemic drugs with binary endpoints. Drug Information Journal 31(4): 1291-300, 1997.

Tu D. Two one-sided tests procedures in establishing therapeutic equivalence with binary clinical endpoints: fixed sample performances and sample size determination. J Statistical Computing & Simulations 59: 271-90, 1997.

1996

Bacon M. Nurses in oncology: the evolving role of nurses in clinical trials. Oncology Advisor 4(2): 1, 1996.

Bacon M. Clinical trials - the maze of regulations. Can Onc Nursing J 6(3): 120-2, 1996.

Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Jr., Barnhill RL, Wanebo HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224: 255-66, 1996.

Bow EJ, Mandell LA, Louie TJ, Feld R, Palmer M, Zee B, Pater J. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 125: 183-90, 1996.

Coppin CML, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14: 2901-7, 1996.

Dancey J, Eisenhauer E. Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-38, 1996.

Dent S, Eisenhauer E. Phase I trial design:  are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.

Eisenhauer E, Vermorken J. New drugs in gynecologic oncology. Curr Opin Oncol 8: 408-14, 1996.

Eisenhauer E. The role of paclitaxel in ovarian cancer treatment. Oncology and Hematology 4: 7-9, 1996.

Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 14(2): 203-6, 1996.

Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13: 343-5, 1996.

Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E. Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol 7: 205-7, 1996.

Nicklee T, Crump M, Hedley D. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry 25(3): 205-10, 1996.

O'Connell MJ, Kahn MJ, Erlichman C, Goldberg RM, Shepherd LE. Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy (letter to the editor). J Clin Oncol 14: 2887, 1996.

Osoba D, Dancey J, Zee B, Myles J, Pater J. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst Monogr No.20: 107-11, 1996.

Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology 53(suppl 1): 92-5, 1996.

Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14: 2709-12, 1996.

Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 14: 2731-7, 1996.

Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K. Randomized double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083-90, 1996.

Shepherd FA, Latreille J, Paul K, Eisenhauer E. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer. Semin Oncol 23(6) Suppl 16: 84-90, 1996.

Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. Ann Oncol 7: 311-3, 1996.

Shepherd FA, Latreille J, Crump M. Phase I study of paclitaxel (TaxolR) and ifosfamide in previously untreated patients with advanced non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Lung Cancer 16(1): 122, 1996.

Siu L, Shepherd F, Murray N, Feld R, Pater J, Zee B. The influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14(3): 821-8, 1996.

Swenerton K, Hoskins P, Stuart G, Batist G, Pike J, Onetto N, Fisher B, Eisenhauer E. A phase I study of biweekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. Ann Oncol 7: 1077-9, 1996.

Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM. Docetaxel in patients with metastatic breast cancer. a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14: 422-8, 1996.

Tu D, Gross AJ. A Bartlett type correction for the subject-years method in comparing survival data to a standard population. Statistics & Probability Letters 29: 149-57, 1996.

Viallet J, Stewart D, Shepherd F, Ayoub J, Cormier Y, DiPietro N, Steward W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the NCIC Clinical Trials Group. Lung Cancer 15: 367-73, 1996.

1995

Belch A, Eisenhauer E, Muldal A, Browman G, Klasa R, Osterwalder B. Phase II study of subcutaneous rHu interleukin-2 and rHu-interferon alpha-2a in previously treated patients with multiple myeloma. Ann Oncol 6: 721-3, 1995.

Bramwell V, Eisenhauer E, Blackstein M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6: 847-9, 1995.

Browman G, Bergsagel D, Sicheri D, O'Reilly S, Wilson K, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: a study of the NCIC Clinical Trials Group. J Clin Oncol 13(9): 2354-60, 1995.

Cairncross G, Eisenhauer E. Response and Control:  lessons from oligodendroglioma (letter to the editor). J Clin Oncol 13: 2475, 1995.

Dancey J, Steward W. The role of vindesine in oncology - recommendations after 10 years' experience. Anti Cancer Drugs 6: 1-12, 1995.

Eisenhauer E, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Can 31A(Suppl.4): 11, 1995.

Eisenhauer E. Docetaxel:  current status and future prospects. J Clin Oncol 13(12): 2865-8, 1995.

Ghersi D, Stewart LA, Parmar MKB, Coppin C, Martinez-Pineiro J, Raghavan D, Wallace M. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urology 75: 206-13, 1995.

Goss G, Muldal A, Lohmann R, Taylor M, Lopez P, Armitage G, Steward W. Didemnin B in favourable histology non-Hodgkin's lymphoma.  A phase II study of the NCIC Clinical Trials Group. Invest New Drugs 13: 257-60, 1995.

Grever M, Kopecky K, Foucar MK, Bennett JM, Habermann T, Rai K, Eisenhauer E, Cheson BD. Reply to the letter Optimal Treatment for untreated patients with hairy cell leukemia? J Clin Oncol 13: 2677-9, 1995.

Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13: 974-82, 1995.

Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, Pater J, Shepherd L, Zee B, Seitz JF, Milan C, Pignon JP. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. (International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators). Lancet 345: 939-44, 1995.

Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L, Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Supportive Care in Cancer 3(5): 307-13, 1995.

Osoba D, Till J, Pater J, Young J. Health-related quality of life:  measurement and clinical application (a workshop report). Can J Oncol 5(1): 338-43, 1995.

Palmer M, McBride J. Working towards a national oncology pharmacists network. Hospital Pharmacy Practice 3(3): 24-5, 1995.

Pater J, Zee B, Myles J, Pignon J, Milan C, Sahmoud T, Torri V, Marsoni S. A proposal for a new approach to intergroup cancer trials. Eur J Can 31A(12): 1921-3, 1995.

Pater J, Warr D. Roila original article (dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer (letter to editor). N Engl J Med 332: 1653, 1995.

Payne D, Coy P, Hodson I, Murray N, Pater J, Wilson K. Coy et al. original article (Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer) (letter to editor). Int J Rad Oncol Biol Phys 31(1): 207, 1995.

Pearcey R, Stuart G, MacLean G, Nation J, Arthur K, Lukka H, Jeffrey J, James K, Brundage M. Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 58: 34-41, 1995.

Piccart M, Raymond E, Aapro M, Eisenhauer E, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines:  current status and future prospects. Eur J Can 31A(Suppl 7): 1-10, 1995.

Raby B, Pater J, Mackillop W. Does Knowledge Guide Practice?  Another look at the management of non-small-cell lung cancer. J Clin Oncol 13(8): 1904-11, 1995.

1994

Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. J Natl Cancer Inst 86(4): 306-9, 1994.

Bacon M. The Nursing implications of an international clinical trial of taxol. Gynecol Oncol Nursing 4(1): 21-4, 1994.

Bacon M. Cancer clinical trials - nursing opportunities. Gynecol Oncol Nursing 4(4): 19-21, 1994.

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12(10): 2013-21, 1994.

Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. Ann Oncol 5: 283-5, 1994.

Coy P, Hodson I, Murray N, Pater J, Payne D, Arnold A, Kostashuk E, Dixon P, Evans W, Zee B, Sadura A, Ayoub J, Levitt M, Wierzbicki R, Feld R, Maroun J, Wilson K. Patterns of failure following locoregional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Rad Oncol Biol Phys 28: 355-62, 1994.

Eisenhauer E, Lippman S, Kavanagh J, Parades-Espinoza M, Arnold A, Hong W, Massimini G, Schleuninger U, Bollag W, Holdener E, Krakoff I. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 8: 1622-5, 1994.

Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Gianni L, Myles J, van der Burg M, Kerr I, Vermorken J, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer:  high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12): 2654-66, 1994.

Goss G, Letendre F, Stewart D, Shepherd F, Schacter L, Hoogendoorn P, Eisenhauer E. Phase II study of elsamitrucin in non-small cell lung cancer. Invest New Drugs 12: 315-7, 1994.

Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J. The effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the NCIC Clinical Trials Group. J Clin Oncol 12(5): 1050-7, 1994.

Knowling M, Bramwell V, Eisenhauer E, Boos G, Bodurtha A, Quirt I. Phase II trial of 10-EDAM in advanced soft tissue sarcoma.  A study of the Canadian Sarcoma Group and the NCIC Clinical Trials Group. Ann Oncol 5(8): 766-8, 1994.

Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma: a phase II trial of the NCIC Clinical Trials Group. Ann Oncol 5(4): 185-7, 1994.

Murray N, Coppin C, Coldman A, Pater J, Rapp E. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol 12(11): 2333-9, 1994.

Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research 3: 353-64, 1994.

Pater J, Mackillop W, Brundage M, Goodwin P, Osoba D, Llewellyn-Thomas H. Outcome measurements in oncology (symposium). Ann R Coll Phy Surg Can 27(3): 174-8, 1994.

Pater J. Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer:  A NCIC Clinical Trials Group perspective. Statistics in Medicine 13: 1337-40, 1994.

Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Supportive Care in Cancer 2(3): 161-6, 1994.

Pritchard KI. Clinical cooperative trials of the NCIC Clinical Trials Group Breast Cancer Site Group. Cancer 74(Suppl 3): 1150-5, 1994.

Shepherd L, Ottaway J, Myles J, Levine M. Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer (letter to the editor). J Clin Oncol 12(11): 2514-5, 1994.

Till J, Osoba D, Pater J, Young J. Research on health-related quality of life: dissemination into practical applications. Quality of Life Research 3: 279-83, 1994.

1993

Allen D, Baak J, Belpomme D, Berek J, Bertelsen K, Ten Bokkel-Huinink W, van der Burg M, Calvert A, Conte P, Dauplat J, Eisenhauer E, Favalli G, Hacker N, Hamilton T, Hansen H, Hansen M, van Houwelingen H, Kaye S, Levin L, Lund B, Neijt J, Ozols R, Piccart M, Rustin G, Sessa C, Soutter W, Thigpen T, Trope C, Vermorken J, de Vries E. Advanced epithelial ovarian cancer:  1993 consensus statements. Ann Oncol 4(Suppl.4): 83-8, 1993.

Balch C, Urist M, Karakousis C, Smith T, Temple W, Drzewiecki K, Jewell W, Bartolucci A, Mihm M, Jr., Barnhill R, Wanebo H. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm).  Results of a multi-institutional randomized surgical trial. Ann Surg 218(3): 262-9, 1993.

Bélanger K, Jolivet J, Maroun J, Stewart D, Grillo-Lopez A, Whitfield L, Wainman N, Eisenhauer E. Phase I pharmacokinetic study of DUP-937. Invest New Drugs 11(4): 301-8, 1993.

Brundage M, Pater J, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 85(14): 1138-48, 1993.

Eisenhauer E. Taxol in advanced non-small cell lung cancer: plus ca change? J Natl Cancer Inst 85(5): 346-7, 1993.

Feld R, Pater J, Goodwin P, Grossman R, Coy P, Murray N. The restaging of responding patients with limited small cell lung cancer -- is it really useful? Chest 103(4): 1010-6, 1993.

Gregg R, Kaizer L, Fine S, Gelmon K, Wielgosz G, Eisenhauer E. A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 4(8): 693-4, 1993.

Hansen H, Eisenhauer E, Hansen M, Neijt J, Piccart M, Sessa C, Thigpen T. New cytostatic drugs in ovarian cancer. Ann Oncol 4(Suppl.4): 63-70, 1993.

Johnston D. Lessons learned from coordinating a pivotal clinical trial. J Clin Res and Drug Development 7: 31-9, 1993.

Levitt M, Warr D, Yelle L, Rayner H, Lofters W, Perrault D, Wilson K, Latreille J, Potvin M, Warner E, Pritchard K, Palmer M, Zee B, Pater J. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328(15): 1081-4, 1993.

Maroun JA, Skillings J, MacCormick R, Potvin M, Wielgosz G, Davidson JR, Eisenhauer E. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma: A Canadian National Cancer Institute Clinical Trial Group study. Invest New Drugs 11: 235-7, 1993.

Mertens W, Eisenhauer E, Moore M, Venner P, Stewart D, Muldal A, Wong D. Gemcitabine in advanced renal cell carcinoma.  A phase II study of the NCIC Clinical Trials Group. Ann Oncol 4: 331-2, 1993.

Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell V, Weinerman BH, Gospodarowicz MK, Burns BF, Sargeant A-M, Shepherd LE, Zee B, Hryniuk WM. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 329: 1770-6, 1993.

Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee B, Payne D, Kostashuk E, Evans W, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11(2): 336-44, 1993.

Niezgoda H, Pater J. A validation study of the domains of the core EORTC quality of life questionnaire. Quality of Life Research 2: 319-25, 1993.

Osoba D, Pater J. Assessing quality of life in clinical trials (letter to the editor). Ann Oncol 4(6): 520, 1993.

Pater JL. Polychemotherapy in advanced non-small cell lung cancer.(letter to the editor). Lancet 342: 741-2, 1993.

Pater J, Bacon M. Guest Editorial:  Clinical Trials Group of NCIC. Can Onc Nursing J 3(3): 114, 1993.

Pater J. The use of data monitoring committees in Canadian trial groups. Statistics in Medicine 12: 505-8, 1993.

Pater J. Implications for clinical research - cancer treatment under pressure. Can J Oncol 3(3): 44-5, 1993.

Peereboom DM, Donehower RC, Eisenhauer E, McGuire WMP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky E. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 11(5): 885-90, 1993.

Reyno L, Egorin M, Canetta R, Jodrell D, Swenerton K, Pater J, Burroughs J, Novak M, Sridhara R. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11(6): 1156-64, 1993.

Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4) Suppl 3: 1-15, 1993.

Rusthoven J, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal A, Lu H, Onetto N, Swenerton K, Jeffrey J. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma. J Natl Cancer Inst 85(10): 823-5, 1993.

Shore T, Eisenhauer E, Quirt I, Belanger K, Lohmann R, Silver H, Wielgosz G. A phase II study of DuP-937 (Teloxantrone) in metastatic malignant melanoma: a study of the NCIC Clinical Trials Group. Ann Oncol 4(8): 695-6, 1993.

Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP. Polychemotherapy in advanced non-small cell lung cancer:  a meta-analysis. Lancet 342: 19-21, 1993.

Stewart D, Eisenhauer E, Macdonald D, Cairncross G, Langleben A. Phase II study of tiazofurin in gliomas in adults. J Neuro Oncol 15: 175-9, 1993.

Thigpen T, Bertelsen K, Eisenhauer E, Hacker N, Lund B, Sessa C. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol 4(Suppl.4): 35-40, 1993.

Vandenberg T, Pritchard K, Eisenhauer E, Trudeau ME, Norris BD, Lopez P, Verma S, Buckman RA, Muldal A. Phase II study of weekly edatrexate as first line chemotherapy for metastatic breast cancer.  A NCIC Clinical Trials Group Study. J Clin Oncol 11(7): 1241-4, 1993.

Verma S, Quirt IC, Eisenhauer E, Iscoe N, Young V, Bodurtha A, Davidson J. A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A NCIC Clinical Trials Group Study. Ann Oncol 4: 254-5, 1993.

Vermorken J, Ten Bokkel-Huinink W, Eisenhauer E, Favalli G, Belpomme D, Conte P, Kaye S. Carboplatin versus cisplatin in ovarian cancer. Ann Oncol 4(Suppl.4): 41-8, 1993.

Warr D, Willan A, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O'Connell G, Osoba D, Wilson K, Davis A, Johnston D. A randomised, double-blind comparison of granisetron with high dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Can 29A(1): 33-6, 1993.

1992

Bow E, Pater J, Louie T, Feld R, Mandell L, Robson H, Chow A, Belch A, Miedzinski L, Paul N, Elliott C, Willan A. Reduction in clinical response to empiric antimicrobrial therapy of febrile granulocytopenic patients receiving trimethoprim/sulfamethoxazole for infection prophylaxis. Can J Infect Dis 3(5): 235-9, 1992.

Browman G, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater J. Modified adriamycin-vincristine-dexamethasone (M-VAD) in primary refractory and relapsed plasma cell myeloma:  an NCI (Canada) pilot study. Br J Haematol 82: 555-9, 1992.

Eisenhauer E.A. New drug investigation in Canada: how well placed are we? Can J Oncol 2(1): 67-72, 1992.

Loehrer PJ, Sr., Einhorn LH, Elson PJ, Crawford DE, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, Blumenstein B, Trump D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma:  a cooperative group study. J Clin Oncol 10(7): 1066-73, 1992.

Osoba D. The Quality of Life Committee of the NCIC Clinical Trials Group:  organization and functions. Quality of Life Research 1: 211-8, 1992.

Paul N, Pater J. Industry involvement in cooperative oncology group studies: results of a survey of study nurses/institutional data managers. J Clin Res Pharmacoepidemiology 6: 39-46, 1992.

Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality of life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 84(13): 1023-6, 1992.

Shepherd F, Rusthoven J, Eisenhauer E, Goss P. Phase I trial of granulocyte, macrophage-colony stimulating factor with high dose cisplatin and etoposide for treatment of small cell lung cancer. A study of the NCIC Clinical Trials Group. J Natl Cancer Inst 84(1): 59-60, 1992.

Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D, Weinerman B. A phase II study of recombinant tumour necrosis factor in renal cell carcinoma. J Immunother 11: 67-70, 1992.

Stewart D, Eisenhauer E, Skillings J, Pritchard K, Buckman R, Vandenberg T, Verma S, Aitken S, Norris B. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer. A NCIC Clinical Trials Group Study. Ann Oncol 3: 201-4, 1992.

Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the NCIC Clinical Trials Group. J Clin Oncol 10(5): 718-26, 1992.

Weinerman B, Eisenhauer E, Stewart D, Mertens W, Tannock I, Venner P, Spaulding R. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 3: 83-4, 1992.

Weinerman B, Shah A, Fields A, Cripps C, Wilson K, McCormick R, Temple W, Maroun J, Bogues W, Pater J, Zee B. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 15(6): 518-23, 1992.

1991

Calandra,T, Zinner,SH, Glauser,MP, Meunier,F, Viscoli,C, Feld,R, Gaya,H, Klastersky,J. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163: 951-8, 1991.

Belch A, Bergsagel D, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9(8): 1397-402, 1991.

Eisenhauer E, Wierzbicki R, Knowling M, Bramwell V, Quirt I. Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Studies of the Canadian Sarcoma Group and the NCIC Clinical Trials Group. Ann Oncol 2: 689-90, 1991.

Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E, Zee B, Whitfield L. A phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DUP937). Cancer Research 6317-22, 1991.

Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-93, 1991.

Monga M, Carmichael J, Shelley W, Kirk M, Krepart G, Jeffrey JF, Pater J. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 43: 195-7, 1991.

Pater J. Facilitation and funding of interface research. Can J Oncol 1(2): 45-9, 1991.

Quirt I, Shelley W, Pater J, Bodurtha A, McCulloch P, McPherson TA, Paterson A, Prentice R, Silver H, Willan A, Wilson K, Zee B. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole:  a phase III study by the NCIC Clinical Trials Group. J Clin Oncol 9(5): 729-35, 1991. (Abstract)

Rusthoven J, Pater J, Kaizer L, Wilson K, Osoba D, Latreille J, Findlay B, Lofters W, Warr D, Laberge F, Vandenberg T, Zee B, Goodlow J, Johnston D, Smaldone L. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801)  with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol 2: 681-6, 1991.

Rusthoven J, Levin L, Eisenhauer E, Mazurka J, Carmichael J, O'Connell G, Bryson P, Hirte H, Koski B. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 83(23): 1748-53, 1991.

Shepherd F, MacCormick R, Eisenhauer E. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer. A study of the NCIC Clinical Trials Group. Ann Oncol 2: 772-3, 1991.

Skillings J, Levine M, Rayner H, Eisenhauer E, Erlichman C, Germond C, Kerr I, Lofters W, Maroun J, Yoshida S. Current Review. Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication. Can Med Assoc J 144: 297-301, 1991.

Skillings J, Cripps C, Eisenhauer E, Pater J, Verma S, Walde D. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 9: 79-82, 1991.

Venner P, Eisenhauer E, Wierzbicki R, Johnston J. Phase II study of 2'- deoxycoformycin in patients with renal cell carcinoma. A NCIC Clinical Trials Group Study. Invest New Drugs 9: 273-5, 1991.

Warr D, Willan A, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Lofters W, Osoba D, Laberge F, Latreille J, Pater J. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy induced emesis. J Natl Cancer Inst 83(16): 1169-73, 1991.

Yelle L, Bergsagel D, Basco V, Brown T, Bush R, Gillies J, Israels L, Miller A, Rideout D, Whitelaw D, Willan A, Pater J. Combined modality therapy of Hodgkin's disease: ten-year results of NCIC Clinical Trials Group multicentre clinical trial. J Clin Oncol 9(11): 1983-93, 1991.

1990

Blackstein M, Eisenhauer E, Wierzbicki R, Yoshida S. Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: An NCI Canada Clinical Trials Group Study. J Clin Oncol 8(3): 385-9, 1990.

Cairncross G, Eisenhauer E, Macdonald DR, Rathbone M, Moore M, Sawka C, MacCormick R, Kerr I. Phase II study of trimetrexate in recurrent anaplastic glioma. An NCI Canada Clinical Trials Group Study. Can J Neurol Sci 17: 21-3, 1990.

Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. An NCI Canada Clinical Trials Group Study. Invest New Drugs 8: 283-7, 1990.

Evans W, Eisenhauer E, Cormier Y, Ayoub J, Wierzbicki R, Laberge F, Shepherd F. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8(3): 390-5, 1990.

Iscoe N, Eisenhauer E, Bodurtha A. Phase II study of trimetrexate in malignant melanoma: a NCIC Clinical Trials Group Study. Invest New Drugs 8: 121-3, 1990.

Jaakkimainen L, Goodwin P, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a NCIC Clinical Trials Group randomized trial in non-small cell lung cancer. J Clin Oncol 8(8): 1301-9, 1990.

Maroun J, Stewart D, Verma S, Evans WK, Eisenhauer E. Phase I study of acivicin and cisplatin in non-small cell lung cancer. Am J Clin Oncol (CCT)13(5): 401-4, 1990.

1989

Bramwell V, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. A Canadian Sarcoma-NCI Canada Clinical Trials Group Study. J Natl Cancer Inst 81(19): 1496-9, 1989.

O'Dwyer PJ, King SA, Eisenhauer E, Grem JL, Hoth DF. Hypersensitivity reactions to deoxycoformycin. Cancer Chemother Pharmacol 23: 173-5, 1989.

1988

Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 57: 94-9, 1988.

Burns BF, Comrie W, Willan A, McCaughey WTE. Observer variation in the pathologic diagnosis of malignant lymphoma in Canada. Cancer 62: 314-8, 1988.

Coy P, Hodson I, Payne DG, Evans WK, Feld R, MacDonald AS, Osoba D, Pater J. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer.  Initial results of a Canadian multicenter randomized trial. Int J Rad Oncol Biol Phys 14: 219-26, 1988.

Eisenhauer E, Zee B, Pater J, Walsh W. Trimetrexate: Predictors of severe or life-threatening toxic effects. J Natl Cancer Inst 80: 1318-22, 1988.

Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 6: 327-9, 1988.

Elliott C, Pater J. The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clin Invest Med 11(5): 327-30, 1988.

Evans W, Eisenhauer E, Hughes P, Maroun J, Ayoub J, Shepherd F, Feld R. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the NCIC Clinical Trials Group. Br J Cancer 58: 464-8, 1988.

Goodwin P, Feld R, Evans W, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small cell lung cancer. J Clin Oncol 6(10): 1537-47, 1988.

Johnston J, Eisenhauer E, Corbett WEN, Scott J, Zaentz S. The efficacy of 2'-deoxycoformycin in hairy cell leukemia: a study of the NCIC Clinical Trials Group. J Natl Cancer Inst 80(10): 765-9, 1988.

Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y, Willan A. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a NCIC Clinical Trials Group Report. J Clin Oncol 6(8): 1254-63, 1988.

Osoba D, Erlichman C, Willan A, Brigden ML, Geggie P, Pater J, Rusthoven J, Wilson KS. Failure of methylprednisolone acetate to prolong the antinauseant effect of intravenous methylprednisolone sodium succinate in patients receiving chemotherapy. Clin Invest Med 11(5): 377-9, 1988.

Perrault D, Logan DM, Stewart D, Bramwell V, Paterson AHG, Eisenhauer E. Phase II study of flutamide in patients with metastatic breast cancer. A NCIC Clinical Trials Group Study. Invest New Drugs 6: 207-10, 1988.

Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans WK, Hodson I, Clark D, Feld R, Arnold A, Ayoub J, Wilson KS, Latreille J, Wierzbicki RF, Hill D. Chemotherapy can prolong survival in patients with advanced non- small-cell lung cancer -- report of a Canadian multicenter randomized trial. J Clin Oncol 6(4): 633-41, 1988.

Ross W, Carmichael J, Shelley W. Advanced carcinoma of the ovary with central nervous system relapse. Gynecol Oncol 30: 398-406, 1988.

Shelley W, Carmichael J, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, Willan A, Wilson K. Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. Gynecol Oncol 29: 208-21, 1988.

Shelley W, Starreveld A, Carmichael J, O'Connell G, Roy M, Swenerton K. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy. Obstet Gynecol 71(3): 327-32, 1988.

Temple WJ, Bramwell V, Eisenhauer E, Jenkin RDT, Langer F, Worth AJ. Guidelines for the surgical management of soft-tissue sarcoma. Report of the Canadian Sarcoma Group. Can J Surg 31(6): 410-2, 1988.

Willan A. Using the maximum test statistic in the two-period crossover clinical trial. Biometrics 44: 211-8, 1988.

1987

Carmichael J, Shelley W, Brown L, Fraser R, Kirk M, Krepart G, Levitt M, Roy M, Willan A, Wilson KS. A predictive index of cure versus no cure in advanced ovarian carcinoma patients -- replacement of second-look laparotomy as a diagnostic test. Gynecol Oncol 27: 269-78, 1987.

Eisenhauer E, Maroun J, Fields A, Walde PLD. Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A NCIC Clinical Trials Group Study. Invest New Drugs 5: 375-8, 1987.

Eisenhauer E, Silver K, Venner P, Thirlwell M, Weinerman B, Coppin C. Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. Br J Cancer 55: 541-2, 1987.

Evans W, Feld R, Murray N, Willan A, Coy P, Osoba D, Shepherd F, Clark D, Levitt M, MacDonald A, Wilson K, Shelley W, Pater J. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107: 451-8, 1987.

Feld R, Evans WK, Coy P, Hodson I, MacDonald A, Osoba D, Payne D, Shelley W, Pater J. Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5(9): 1401-9, 1987.

Hollinshead A, Stewart THM, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Cancer 60: 1249-62, 1987.

Jolivet J, Landry L, Pinard MF, McCormack JJ, Tong WP, Eisenhauer E. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 20: 169-72, 1987.

Maroun J, Eisenhauer E, Cripps C, Maksymiuk A. Phase II study of tiazofurin in colorectal cancer. Cancer Treat Rep 71(12): 1297-8, 1987.

McCulloch P, Eisenhauer E, Shibata H, Young V. Phase II study of intravenous menogaril in patients with malignant melanoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 71(7-8): 771-2, 1987.

O'Connell G, Shelley W, Carmichael J, Fraser R, Kirk M, Krepart G, Levin L, Swenerton K. High dose intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma. Cancer Treat Rep 71(5): 455-8, 1987.

Pater J, Carmichael J, Krepart G, Fraser R, Roy M, Kirk M, Levitt M, Brown L, Wilson K, Shelley W, Willan A. Second line chemotherapy of stage III-IV ovarian carcinoma: A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 71(3): 277-81, 1987.

Quirt I, Eisenhauer E, Bramwell V, Knowling M, Grafton C, Hirte W, Cripps M, Maksymiuk A. Phase II study of mitroxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas. Cancer Treat Rep 71(11): 1109-10, 1987.

Wilson K, Shelley W, Belch A, Brandes L, Bergsagel D, Klimo P, White D, Willan A. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. Cancer Treat Rep 71(10): 981-2, 1987.

1986

Band P, Maroun J, Pritchard K, Stewart D, Coppin C, Wilson K, Eisenhauer E. Phase II study of lonidamine in patients with metastatic breast cancer. Cancer Treat Rep 70(11): 1305-10, 1986.

Eisenhauer E, Weinerman B, Kerr I, Quirt I. Toxicity of oral N-methylformamide in three phase II trials. A report from the NCI Canada Clinical Trials Group. Cancer Treat Rep 70(7): 881-3, 1986.

Eisenhauer E, Evans W, Raghavan D, Desmeules M, Murray N, Stuart-Harris R, Wilson K. Phase II study of mitoxantrone in patients with mesothelioma: a NCI Canada Clinical Trials Group study. Cancer Treat Rep 70(8): 1029-30, 1986.

Eisenhauer E, Swenerton K, Sturgeon J, Fine S, O'Reilly S. Phase II study of carboplatin in patients with ovarian carcinoma. An NCI Canada Clinical Trials Group Study. Cancer Treat Rep 70: 1195-8, 1986.

Evans W, Feld R, Murray N, Pater J, Shelley W, Willan A, Osoba D, Levitt M, Coy P, Hodson I, Payne D, MacDonald A. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Semin Oncol 13: 10-6, 1986.

Maroun J, Maksymiuk A, Eisenhauer E, Stewart D, Young V, Pater J. Phase II study of acivicin in non-small cell lung cancer. A Canadian National Cancer Institute study. Cancer Treat Rep 70(11): 1327-8, 1986.

Osoba D, Erlichman C, Willan A, Levitt M, Pater J. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. Clin Invest Med 9(4): 225-31, 1986.

Pater J, Eisenhauer E, Shelley W, Willan A. Testing hypotheses in clinical trials: Experience of the NCIC Clinical Trials Group (letter to the editor). Cancer Treat Rep 70(9): 1133-6, 1986.

Pater J, Weir L. Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients -- a critical survey. J Clin Oncol 4(3): 346-52, 1986.

Sawka CA, Pritchard KI, Paterson AHG, Sutherland DJA, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Research 46: 3152-6, 1986.

Weinerman B, Eisenhauer E, Besner JG, Coppin C, Stewart D, Band P. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 70(6): 751-4, 1986.

Willan A, Pater J. Using baseline measurements in the two period crossover clinical trial. Controlled Clin Trials 7(4): 282-9, 1986.

Willan A, Pater J. Carryover and the two period crossover clinical trial. Biometrics 42(3): 593-9, 1986.

1985

Eisenhauer E, Kerr I, Bodurtha A, Iscoe N, McCulloch P, Pritchard K, Quirt I. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 3: 303-5, 1985.

Eisenhauer E, Quirt I, Connors JM, Maroun J, Skillings J. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 3: 307-10, 1985.

Feld R, Louie TJ, Mandell L, Bow EJ, Robson HG, Chow A, Belch A, Miedzinski L, Rachlis A, Pater J, Willan A. A multicentre comparative trial of tobramycin and ticarcillin versus moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med 145: 1083-8, 1985.

Klaassen D, Starreveld A, Shelley W, Miller A, Boyes D, Gerulath A, Levitt M. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. Int J Rad Oncol Biol Phys 11: 1801-4, 1985.

Shelley W, Quirt I, Bodurtha A, Iscoe N, Russell J, Paterson A, Young V. Lomustine, vincristine and procarbazine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 69(9): 941-4, 1985.

Willan A, Pater J. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. J Chron Dis 38(7): 603-8, 1985.

1984

Eisenhauer E, Bowman D, Pritchard K, Paterson AHG, Ragaz J, Geggie P, Maxwell I. Tamoxifen and conjugated estrogens (premarin) followed by sequenced methotrexate and 5-fluorouracil in refractory advanced breast cancer. Cancer Treat Rep 68(11): 1421-2, 1984.

Maroun JA, Fields AL, Pater JL, Stewart DJ, Cripps C, Eisenhauer E. Phase II study of acivicin in colorectal carcinoma: a NCIC Clinical Trials Group study. Cancer Treat Rep 68(9): 1121-3, 1984.

Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Can Treat Rev 11: 257-64, 1984.

Quirt IC, Shelley WE, Osoba D, Dent PB, McCulloch PB, Paterson AHG, Evans WK, Shepherd FA, Baker ML, Bodurtha AJ, Norvell ST, Maroun JA, Thirlwell MP, Weinerman B, Schipper H, Wilson KS, Nimmagadda RBV, Gapski JAP, Pritchard KI, Walde PLD, Duffin JM, Aitken SE. Vinblastine, bleomycin and cis-platinum for the treatment of metastatic malignant melanoma. NCIC Clinical Trials Group Melanoma Group. J Clin Oncol 2: 131-4, 1984.

Pater J, Willan A. Clinical trials as diagnostic tests. Controlled Clin Trials 5: 107-13, 1984.

Pater J, Willan A. Methodologic issues in trials of antiemetics. J Clin Oncol 2(5): 484-7, 1984.

Riopelle RJ, Dow KE, Eisenhauer E. Some observations on vinca alkaloid and ethanol neurotoxicity using dissociated neuronal cultures. Can J Physiol Pharmacol 62: 1032-6, 1984.

Shelley W, Kersey P, Quirt I, Pater J. Survey of surgical management of malignant melanoma in Canada: optimal margins of excision and lymph-node dissection. Can J Surg 27(2): 190-2, 1984.

1980

Miller AB, Klaassen DJ, Boyes DA, Dodds DJ, Gerulath A, Kirk ME, Levitt M, Pearson JG, Wall C. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Can Med Assoc J 123: 365-71, 1980.

1979

Bergsagel D, Bailey A, Langley G, MacDonald R, White D, Miller A. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743-8, 1979.